Strategic area of application
Dermatology & Cosmetology - Immune, AutoIm & Inflam. diseases - Oncology
Therapeutics, Pharma or Biotech - Medical device
Analytical & Diagnostic services - Cell Therapy - cell biology - Biobanking - Regenerative medicine
Presentation of company's activity
CTI-BIOTECH developed and validated a range of technologies enabling 2D and 3-dimensional tissue engineering using bioreactors, biomaterials and clinical-grade growth factors. CTI-BIOTECH’s research applications include bioassay development, drug screening platforms, biomedical device, cGMP bioprocessing and clinical applications.
CTI-LYON runs pre-clinical and clinical programmes to enable cell therapy applications for diabetes, stroke, cerebral palsy, hemato- immunological diseases, cranio-facial malformations, orthopaedic lesions, cancer.
CTI-BIOTECH's expertise grew from haematology and oncology research and patient based therapy including bone marrow disorders where stem cells fail to grow. Using Cord Blood and Bone Marrow, we use normal and abnormal stem cell populations to understand control mechanisms including cytokine and transcriptional pathways. This led us to investigate human “adult” and cord blood stem cells for haematology‐oncology transplantation. The non‐invasive nature of collection umbilical cord and cord blood offer a distinct advantage over any other sources of adult and embryonic stem cells. Umbilical cord and cord blood cells can be characterized and cryopreserved bio‐banks worldwide. With over 130million children born each year, neonatal is an abundant stem cell source from all genetic and ethnic background. Our research has shown that cells from all three germ layers can be produced from umbilical cord, cord blood and bone marrow stem cells. We have developed routine protocols for isolation of defined cell populations from extremely immature stem cell compartments, through to more mature progenitor cells, which have allowed defined tissue engineering and regenerative procedures to be advanced. The most significant development of our work has been the development of a protocol for the production of karyotypically normal Cord Blood‐derived Embryonic‐like stem cells (CBE’s), which have the ability to form embryoid body‐like structures and to express the majority of Embryonic Stem Cell markers. It is also possible to subculture these cells for ex vivo expansion for over 12 weeks, whilst maintaining their immaturity. This research, published in 2005, is the first production of a clone of embryonic‐like cells from a non‐embryonic tissue.
We further demonstrated the pluripotent nature of umbilical cord and cord blood stem cells that can be differentiated into endodermal, mesodermal and ectodermal tissues including neural, endothelial, hepatic, and pancreatic tissues. Conventional cell culture methods employ 2‐ dimensional culture systems to propagate cells in vitro. Although this approach is useful to understand key biological features like the cell cycle, growth factor stimulation, proliferation rates and signal transduction, the large scale clinical grade ex‐vivo tissue and organ expansion generation calls for 3‐dimensional Tissue Bio‐engineering. Our preliminary work with bioreactors has demonstrated that they allow continuous rotation, expansion and endogenous extracellular matrix production in a shear stress‐free environment favouring development into functional 3‐D tissues. A key finding in this was our ability to expand, maintain and differentiate CBE’s into hepatic and neural progenitors in 3‐dimensions with and without supporting bio‐scaffolds.
Key features of company
We host a variable team of international researchers with extensive expertise in stem cell biology and cord blood bio‐processing as well as stem cell cultures, cell-based bioassays and tissue engineering.
CTI-BIOTECH is an accredited scientific biobank for biomedical research using human tissue samples.
CTI BIOTECH is a founding partner of the IMODI project (Innovative Models Initiative Against Cancer) To accelerate therapeutic innovation and identification of anticancer therapies, with a rapid transfer to the clinic, to the direct benefit of patients. www.imodi-cancer.org
IMODI is one of Europe's largest company-hospital-university networks, 41M Euros project part funded with French government the companies involved. IMODI will create platforms for personalized medicine applied to treat Cancer.
Skills and know-how
CTI-BIOTECH's expertise includes 3‐dimensional tissue engineering and bioreactor systems, flow cytometry, molecular biology, microarray, proteomics, laser‐scanning confocal microscopy, bioprocessing. using adult (bone marrow, adipose tissues, cornea) and neonatal stem cells (umbilical cord, cord blood, placenta) as universal vectors for tissue engineering, drug screening, cell therapy and regenerative medicine research.
CTI-BIOTECH further develops innovative predictive cancer models, models of the human tumor microenvironment using humanized mouse models, Cancer Cell line models.